Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companies

Set Alert for Companies

Early Promise Of NextCure’s Novel IO Candidate Continues To Fade

Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.

Clinical Trials ImmunoOncology

Roche's Tecentriq Disappoints In Ovarian Cancer Study

PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.

ImmunoOncology Clinical Trials

Concerns About Eye Toxicity Could Limit GSK’s Myeloma Drug Potential

Company told more measures needed to limit damage to patients' eyes caused by antibody drug conjugate.

Commercial Companies

Stockwatch: Will Coronavirus Drug Developments Rescue The Sector’s Pricing Reputation?

Can the development of coronavirus vaccines and therapeutics reverse the demonization of the pharmaceutical sector brought about by drug price increases?

Coronavirus COVID-19 Pricing Debate

Coronavirus Update: Lower Immune Responses Could See ‘Shake Out’ Of Vaccine Contenders

Leader of London university's vaccine contender hopeful of breakthrough in early 2021, but thinks Oxford's forecast of September overly optimistic.

Coronavirus COVID-19 Companies

Newly Launched Eir Ventures To Target ‘Early Nordic Opportunities’

The Nordic region’s vibrant life sciences ecosystem will be the chief focus for newly created Eir Ventures, a strategic partnership and investment company.  

Commercial Companies

Atox ‘Remains On Track’ Despite ACCUTE Setback

After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.

Clinical Trials Commercial

Merck To Pay Up To $425m For Foghorn’s Gene Regulation Therapies

US major continues its expansion in oncology with an early stage deal with Flagship Pioneering protegés.

Commercial Companies

Hansa Raises $121m To Fund Idefirix Launch

Having recently signed a gene therapy collaboration with Sarepta and received a positive opinion from the CHMP for its kidney transplant therapy, Sweden's Hansa has now raised a substantial sum in a "multiple times oversubscribed" placing.

Financing Rare Diseases
See All
UsernamePublicRestriction

Register